Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sofosbuvir/ledipasvir and ribavirin tolerability and efficacy in pediatric liver transplant recipients.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society - 1 Apr 2017

Huysentruyt Koen, Stephenne Xavier, Varma Sharat, Scheers Isabelle, Leclercq Gisèle, Smets Françoise, Sokal Etienne M

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles
Share to Biliary Atresia
Share to Budd-Chiari Syndrome

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluorenes

Share to Liver Transplantation

Share to Sofosbuvir

Share to Sustained Virologic Response

Share to Uridine Monophosphate

Source

Identifiers

PMID: 28006874
DOI: 10.1002/lt.24692

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sofosbuvir/ledipasvir and ribavirin tolerability and efficacy in pediatric liver transplant recipients.PMID 28006874Read ↗

Pharmacokinetic evaluation of sofosbuvir/velpatasvir for the treatment of Chronic Hepatitis C in pediatrics aged 3 and older.Semantic proximity Read ↗

Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin.Semantic proximity Read ↗

Ledipasvir-sofosbuvir in Adolescents With Chronic Hepatitis C and Hematological Malignancies Undergoing Chemotherapy.Semantic proximity Read ↗

The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection.Semantic proximity Read ↗

[Use of sofosbuvir-based regimens in the treatment of adolescents and children with chronic hepatitis C].Semantic proximity Read ↗

Treatment of hepatitis C in children and adolescents: how far have we reached?Semantic proximity Read ↗

[Ledipasvir/sofosbuvir combination for chronic hepatitis C infection in children and adolescents].Semantic proximity Read ↗

Safety and Efficacy of Ledipasvir/Sofosbuvir in the Treatment of Chronic Hepatitis C Virus Infection in Treatment-Naïve Children without and with Comorbidities.Semantic proximity Read ↗

Meeting the WHO hepatitis C virus elimination goal: Review of treatment in paediatrics.Semantic proximity Read ↗

Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancies: A Pharmacokinetic Study.Semantic proximity Read ↗

Efficacy of Sofosbuvir/Ledipasvir in Adolescents With Chronic Hepatitis C Genotypes 1, 3, and 4: A Real-world Study.Semantic proximity Read ↗

Safety and Efficacy of 8 Weeks Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 4 in Children Aged 4-10 Years.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.